1. Berg MJ, Gross RA, Tomaszewski KJ, Zingaro WM, Haskins LS (2008) Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures. Neurology 71:525–530
2. Dernières données issues de l'enquête de pharmacovigilance de l'ANSM sur les médicaments à base de lévothyroxine. https://ansm.sante.fr/actualites/medicaments-a-base-de-levothyroxine-lansm-publie-les-dernieres-donnees-issues-de-lenquete-de-pharmacovigilance. Accessed 30 Mar 2023
3. EMA guideline on the investigation of bioequivalence: Guideline o the Investigation of Bioequivalence (europa.eu). Accessed 30 Mar 2023
4. EMA: Questions and answers on bioequivalence studies. https://www.ema.europa.eu/en/human-regulatory/research-development/scientific-guidelines/clinical-pharmacology-pharmacokinetics/clinical-pharmacology-pharmacokinetics-questions-answers. Accessed 30 Mar 2023
5. FDA Guidance for Industry Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs — General Considerations. https://www.fda.gov/files/drugs/published/Bioavailability-and-Bioequivalence-Studies-Submitted-in-NDAs-or-INDs-%E2%80%94-General-Considerations.pdf. Accessed 30 Mar 2023